Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep;20(9):1489-1498.
doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

M Rabaglio  1 , Z Sun  2 , K N Price  3 , M Castiglione-Gertsch  4 , H Hawle  4 , B Thürlimann  5 , H Mouridsen  6 , M Campone  7 , J F Forbes  8 , R J Paridaens  9 , M Colleoni  10 , T Pienkowski  11 , J-M Nogaret  12 , I Láng  13 , I Smith  14 , R D Gelber  15 , A Goldhirsch  16 , A S Coates  17 ; BIG 1-98 Collaborative and International Breast Cancer Study Groups
Affiliations
Clinical Trial

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

M Rabaglio et al. Ann Oncol. 2009 Sep.

Abstract

Background: To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial.

Methods: We evaluated 4895 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial who received at least some study medication (median follow-up 60.3 months). Bone fracture information (grade, cause, site) was collected every 6 months during trial treatment.

Results: The incidence of bone fractures was higher among patients treated with letrozole [228 of 2448 women (9.3%)] versus tamoxifen [160 of 2447 women (6.5%)]. The wrist was the most common site of fracture in both treatment groups. Statistically significant risk factors for bone fractures during treatment included age, smoking history, osteoporosis at baseline, previous bone fracture, and previous hormone replacement therapy.

Conclusions: Consistent with other trials comparing aromatase inhibitors to tamoxifen, letrozole was associated with an increase in bone fractures. Benefits of superior disease control associated with letrozole and lower incidence of fracture with tamoxifen should be considered with the risk profile for individual patients.

Trial registration: ClinicalTrials.gov NCT00004205.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subpopulation treatment effect pattern plot analysis of incidence of any bone fracture for letrozole versus tamoxifen among overlapping subpopulations defined according to age at study entry.
Figure 2.
Figure 2.
Univariate Cox model analysis (hazard ratios for time to first bone fracture; letrozole versus tamoxifen) for relevant risk factors among patients with any bone fracture. The box size is proportional to the inverse of the standard error of the hazard ratio estimates. The horizontal line gives the 95% confidence interval.
Figure 3.
Figure 3.
Cumulative incidence of first bone fracture with first disease-free survival (DFS) event as competing events. In the competing risk analysis, for patients who had DFS events before the first bone fracture, the probability of bone fracture at a later time (after the DFS event) was assumed to be zero.
See this image and copyright information in PMC

References

    1. Geisler J, Ekse D, Helle H, et al. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol. 2008;109:90–95. - PubMed
    1. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26:1671–1676. - PubMed
    1. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78–84. - PubMed
    1. BIG 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757. - PubMed
    1. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–2139. - PubMed

Publication types

Associated data